Compare AOUT & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AOUT | MOLN |
|---|---|---|
| Founded | 2020 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.3M | 144.0M |
| IPO Year | 2020 | 2021 |
| Metric | AOUT | MOLN |
|---|---|---|
| Price | $8.89 | $4.04 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $12.50 | $8.38 |
| AVG Volume (30 Days) | ★ 24.3K | 2.1K |
| Earning Date | 03-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 98.94 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $222,322,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.06 | $374.07 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.55 | N/A |
| 52 Week Low | $6.26 | $3.41 |
| 52 Week High | $13.46 | $5.36 |
| Indicator | AOUT | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 41.04 | 41.60 |
| Support Level | $8.33 | $3.94 |
| Resistance Level | $8.91 | $4.54 |
| Average True Range (ATR) | 0.37 | 0.08 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 5.70 | 0.00 |
American Outdoor Brands Inc is engaged in the business of providing outdoor products and accessories for hunting, fishing, camping, shooting, and personal security and defense products. The company designs and produces products and accessories, including shooting supplies, rest, vaults, and other related accessories; premium sportsman knives and tools for fishing and hunting; land management tools for hunting preparedness; harvesting products for post-hunt or post-fishing activities; electro-optical devices, including hunting optics, firearm aiming devices, flashlights, and laser grips; reloading, gunsmithing, and firearm cleaning supplies; and survival, camping, and emergency preparedness products.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.